Low-dose naltrexone, or LDN, is being studied as an off-label option for inflammation-related symptoms, especially chronic pain conditions such as fibromyalgia. Evidence suggests possible pain benefits, but the research is still limited and condition-specific. LDN is not FDA-approved for inflammation and should be considered only after clinician evaluation.
Not sure where to start? Take the 3-min clinical quiz.
See if you qualify →Why do people ask about low-dose naltrexone for inflammation?
People ask about low-dose naltrexone when pain, fatigue, skin flares, or autoimmune-like symptoms keep going even after basic tests look normal. The reason is understandable: some early studies and reviews suggest LDN may help certain inflammation-related symptoms, especially centralized pain, but the evidence is not broad enough to call it a general anti-inflammatory treatment 2.
Inflammation versus immune dysregulation versus chronic pain sensitivity
Inflammation is the immune system’s response to injury, infection, or irritation. Immune dysregulation means the immune system is acting in an unbalanced way, as can happen in autoimmune disease. Chronic pain sensitivity, sometimes called centralized pain, can happen when the nervous system becomes more reactive even without clear tissue damage 2.
These problems can overlap, but they are not the same. That is why a person with fibromyalgia, Crohn’s disease, psoriasis, or complex regional pain syndrome may need a different evaluation and treatment plan, even if the word “inflammation” appears in each discussion 2 5.
Why symptoms can persist even when routine inflammatory markers look normal
Common blood tests such as C-reactive protein or erythrocyte sedimentation rate can miss some symptom drivers. In fibromyalgia, for example, the concern is often not classic joint swelling or high inflammatory markers, but pain processing and central nervous system signaling 2.
That does not mean symptoms are “not real.” It means the next step is usually a careful diagnosis, medication review, sleep review, mood and stress assessment, and screening for conditions that can mimic inflammation, such as thyroid disease, anemia, infection, autoimmune disease, or medication effects.
Where LDN fits among lifestyle care, diagnosis, standard treatments, and off-label options
LDN fits best as a clinician-guided, off-label discussion after the basics are not enough: a clear diagnosis, disease-specific care, sleep and movement support, nutrition, and standard treatments when indicated. It should not replace proven therapy for autoimmune disease, inflammatory bowel disease, psoriasis, or another diagnosed condition.
If you want the deeper medication background, our guide to low-dose naltrexone explains how LDN is discussed in clinical practice, while our article on LDN side effects goes deeper on safety.
What is low-dose naltrexone?
Low-dose naltrexone is naltrexone used at doses much lower than the standard FDA-approved 50 mg tablet for alcohol use disorder and opioid use disorder. In LDN research, lower-dose oral naltrexone has been studied for pain and inflammation-related conditions, but those uses are off-label 1 2.
Naltrexone as an opioid receptor antagonist
Naltrexone is an opioid receptor antagonist, which means it blocks opioid receptors. At standard doses, this effect is used to help reduce the rewarding effects of opioids and alcohol in approved substance-use treatment settings 1.
This same opioid-blocking action is also why naltrexone can be risky for someone taking opioid medications. It can reduce opioid pain relief or trigger withdrawal in a person who is opioid-dependent 1.
How low-dose naltrexone differs from standard-dose naltrexone
The term LDN usually refers to doses far below 50 mg, not a different drug. Reviews often describe LDN studies using about 4.5 mg daily, while a 2024 fibromyalgia randomized trial studied 6 mg once daily 2 4. These are research descriptions, not instructions for what any one person should take.
Why LDN is often compounded into low-dose tablets or capsules
Because commercially available naltrexone is commonly supplied as a 50 mg tablet, low-dose forms often need to be compounded by a licensed pharmacy. Compounding lets a prescriber choose a lower-dose tablet or capsule when clinically appropriate, but compounded medications are not FDA-approved.
How might LDN affect inflammation?
The main theory is that LDN may influence microglia, immune-like cells in the brain and spinal cord, and may affect inflammatory signaling in the nervous system. This is a plausible mechanism, but mechanisms do not prove that LDN improves all inflammatory diseases 2.
The microglia and central nervous system inflammation hypothesis
Microglia help protect the central nervous system. When they stay activated, they may release inflammatory signals linked with pain sensitivity, fatigue, sleep disruption, and “flu-like” body symptoms in some chronic pain states 2.
LDN has been described as a possible glial cell modulator. In plain language, that means it may help turn down overactive nervous-system immune signaling in some people, though this has not been proven for every condition 2.
Toll-like receptor and immune-signaling theories
Some researchers propose that naltrexone may affect Toll-like receptor 4, or TLR4, a receptor involved in innate immune signaling. This is part of the reason LDN is discussed as a possible anti-inflammatory agent in the central nervous system 2.
Endorphin and opioid-receptor rebound theories
Another theory is that brief opioid receptor blockade may lead the body to change endogenous opioids, such as endorphins. This theory is still being studied and may not explain all reported effects 2.
Why proposed mechanisms do not prove clinical benefit
A mechanism can explain why a treatment is worth studying, but it cannot show that it works in real patients. For that, we need randomized trials, safety data, and condition-specific outcomes. LDN has some of that evidence in fibromyalgia, but much less for broad “inflammation” as a general symptom 3 4.
What conditions have been studied?
Fibromyalgia has the most relevant human LDN evidence, while other conditions have smaller studies, early trials, or active research. It is better to ask, “What condition was studied?” than “Does LDN reduce inflammation?” 3.
Fibromyalgia and centralized pain
Fibromyalgia is a chronic pain condition marked by widespread pain, fatigue, sleep problems, and cognitive symptoms. LDN has been studied in fibromyalgia because microglia and central pain signaling may be involved 2 6.
A 2018 clinical trial and later randomized trials helped build interest in LDN for fibromyalgia, but the field still needs larger and more consistent studies before firm conclusions can be made 6 4.
Chronic pain conditions
LDN has also been studied or discussed in chronic pain conditions beyond fibromyalgia. A 2023 family medicine review asked whether LDN is effective in chronic pain management, reflecting that clinicians are interested but the evidence remains condition-specific 7.
Inflammatory skin disease such as psoriasis
Psoriasis is an immune-mediated skin disease, and one 2020 clinical trial studied low-dose naltrexone in psoriasis 5. That does not prove LDN helps every skin condition, but it shows why patients with inflammatory skin disease may hear about it.
Crohn’s disease, multiple sclerosis, and other conditions mentioned in reviews
Reviews have discussed LDN in Crohn’s disease, multiple sclerosis, complex regional pain syndrome, and other conditions 2. These are separate diseases with different risks, so a signal in one condition should not be used as proof for another.
ClinicalTrials.gov also lists ongoing or completed LDN-related studies, including low-dose naltrexone therapy for complex regional pain syndrome and a low-dose naltrexone combination study for migraine, which shows that LDN remains an active research area 8 9.
What is not established for general inflammation
LDN is not established as a general treatment for “chronic inflammation.” It has not been proven to replace NSAIDs, corticosteroids, DMARDs, biologics, physical therapy, gut-directed therapy, or other disease-specific treatments when those are indicated.
What does the human evidence say for inflammation-related symptoms?
The best human evidence is in fibromyalgia, but it is still limited and mixed. Some analyses suggest pain improvement, while newer and larger trials show why certainty remains modest 3 4.
Small early fibromyalgia studies
Early fibromyalgia studies, including a 2018 report, helped raise interest in LDN as a possible option for centralized pain 6. These studies were important, but small studies can overestimate benefit and may not apply to every patient.
The larger 2024 fibromyalgia randomized trial and what it found
A 2024 randomized, double-blind, placebo-controlled trial in women with fibromyalgia compared naltrexone 6 mg once daily with placebo 4. This dose and population are study facts, not personal dosing advice. The trial is important because it added stronger evidence and showed that the field is still evolving.
Meta-analysis findings and why certainty remains limited
A 2024 systematic review and meta-analysis of four randomized trials in fibromyalgia found that LDN was associated with lower pain scores and higher pressure pain thresholds versus placebo, but found no significant difference in Fibromyalgia Impact Questionnaire-Revised scores or pain catastrophizing scores 3.
The same review reported side effects such as vivid dreams and nausea, and serious adverse events were not significantly different from placebo in the included trials 3. Individual results vary, and larger trials are still needed.
Why evidence for one condition should not be applied to every inflammatory disease
A fibromyalgia pain result does not prove benefit for rheumatoid arthritis, ulcerative colitis, psoriasis, multiple sclerosis, or long-term fatigue. Each condition has different biology and different risks if proven treatment is delayed.
Who might discuss LDN with a clinician?
LDN may be worth discussing for people with persistent pain or inflammation-related symptoms after a real evaluation, especially when fibromyalgia or centralized pain is part of the picture. It is not a do-it-yourself anti-inflammatory and is not right for everyone.
- People with fibromyalgia or chronic widespread pain who want to understand off-label options after standard evaluation.
- People with persistent symptoms despite sleep, movement, nutrition, and diagnosis-specific care.
- People with inflammatory skin, gut, neurologic, or autoimmune disease who are curious about LDN but are not planning to stop proven treatment.
- People who can share a full medication list, including opioids, opioid-like medicines, alcohol-use medications, liver-risk medicines, and supplements.
LDN should not replace diagnosis or proven disease-specific therapy. Patients should not stop prescribed anti-inflammatory, autoimmune, pain, or opioid-related treatment without speaking with their clinician.
| Your situation | Sensible next step | Why it matters |
|---|---|---|
| New swelling, fever, rash, blood in stool, weakness, or unexplained weight loss | Get medical evaluation first | These can signal conditions that need prompt diagnosis, not an off-label trial. |
| Fibromyalgia or chronic widespread pain already diagnosed | Ask a clinician whether LDN fits your history | This is where the most relevant human LDN evidence exists, though certainty is still limited. |
| Autoimmune disease such as Crohn’s disease, psoriasis, or multiple sclerosis | Discuss LDN only as an adjunct question with your treating clinician | Disease-specific therapy should not be stopped or delayed. |
| Current opioid medication use or opioid dependence risk | Do not start naltrexone without clinician review | Naltrexone can block opioids or trigger withdrawal. |
| Known liver disease, pregnancy, or breastfeeding | Ask for individualized clinician guidance | Safety depends on medical history, labs, and risk-benefit review. |
3-min quiz
Curious whether LDN fits your history?
At Chia, an online visit starts with a health questionnaire and licensed US provider review. If clinically appropriate, compounded low-dose naltrexone tablets may be prescribed and shipped from a state-licensed 503A pharmacy. A prescription is never guaranteed, and compounded drugs are not FDA-approved. You can also read more about how to buy low-dose naltrexone safely online.
Low-dose naltrexone at Chia: tablets with clinician review
At Chia, low-dose naltrexone tablets are offered through a 100% online visit when a licensed US provider decides they are clinically appropriate. Plans currently start at $59/month on the Low-Dose Naltrexone product page, with up-to-date pricing shown there.
The process starts with a short health questionnaire. Our providers review your medical history, current medicines, liver-risk history, pregnancy or breastfeeding status, and whether you use opioid medications. A prescription is never guaranteed.
When prescribed, LDN is compounded through a state-licensed 503A pharmacy and shipped to your door. Dosing is provider-guided and adjusted only through clinical review, not based on online dosing examples.
Some patients also use Chia’s eligibility quiz to start. If an AI agent is helping organize your care, DoctorMCP at mcp.chia.health can support an agent-assisted access path, but the same rule applies: a licensed provider must review your information before any prescription decision.
What side effects and safety issues should patients know?
Naltrexone safety depends heavily on opioid use, liver risk, and the full medication list. In LDN trials and reviews, side effects were often mild, but the medication still needs clinician oversight 1 3.
Commonly reported effects
Reported LDN side effects include vivid dreams, nausea, headache, diarrhea, dizziness, and sleep changes 3. Not everyone has side effects, and some symptoms may improve with time, but new or worsening symptoms should be discussed with a clinician.
Why opioid use is a major safety issue
Because naltrexone blocks opioid receptors, it can interfere with opioid pain medicines and can trigger withdrawal in someone who is opioid-dependent 1. This includes prescribed opioids, non-prescribed opioids, and some medication-assisted treatment situations.
Liver disease, pregnancy, breastfeeding, and medication-interaction review
Naltrexone labeling includes liver-related warnings, so people with liver disease or elevated liver enzymes need clinician review before use 1. Pregnancy, breastfeeding, alcohol use disorder treatment, opioid use disorder treatment, and other medicines also change the risk-benefit discussion.
When to seek urgent care
Seek urgent care for trouble breathing, severe allergic symptoms, yellowing of the skin or eyes, severe abdominal pain, confusion, severe mood changes, or signs of opioid withdrawal after naltrexone exposure. If symptoms feel dangerous, do not wait for a routine message.
How is LDN typically discussed in dosing research?
LDN dosing numbers online are research context, not instructions. Reviews often describe 4.5 mg daily in LDN trials, and the 2024 fibromyalgia randomized trial studied 6 mg once daily 2 4. Your own dose, if any, should come only from a prescribing clinician.
This is where compounding matters. Since standard naltrexone is commonly available as a 50 mg tablet, lower-dose LDN tablets or capsules often require a compounding pharmacy. The pharmacy should be appropriately licensed, and the prescriber should guide any changes.
- Ask what diagnosis the clinician is treating or helping manage.
- Ask what benefits would count as meaningful for you, such as pain, sleep, function, or flares.
- Ask what side effects should lead you to stop and call.
- Ask how opioid use, liver history, pregnancy, breastfeeding, and other medicines affect safety.
- Ask what proven treatments should continue while LDN is being considered.
How does LDN compare with standard inflammation treatments?
LDN is not a universal replacement for standard inflammation treatment. The right choice depends on the diagnosis, symptom severity, organ involvement, and risk of delaying proven care.
| Option | Where it may fit | Main trade-offs |
|---|---|---|
| Lifestyle foundations | Sleep, paced movement, nutrition, stress support, smoking cessation when relevant | Often helpful but may not be enough for active inflammatory disease. |
| NSAIDs | Short-term pain or inflammation in selected patients | Can affect stomach, kidney, blood pressure, and bleeding risk. |
| Corticosteroids | Short-term control of certain inflammatory flares | Higher risk with long-term use; needs diagnosis-specific supervision. |
| DMARDs or biologics | Autoimmune and inflammatory diseases such as rheumatoid arthritis, psoriasis, or inflammatory bowel disease | More targeted, but require specialist monitoring and infection-risk review. |
| LDN | Off-label adjunct discussion for selected pain or inflammation-related symptoms, especially fibromyalgia-style centralized pain | Evidence is limited, not FDA-approved for inflammation, and unsafe with opioid use without careful review. |
If cost is part of your decision, our guide to low-dose naltrexone cost explains common pricing factors. If you take or are considering other metabolic medications, our article on low-dose naltrexone and tirzepatide explains what to discuss with a clinician.
What changes over time when someone is considering LDN?
LDN is usually judged over weeks to months, not hours. Clinicians often look for changes in function, pain, sleep, side effects, and whether the original diagnosis still fits.
In the first few weeks, side effects such as vivid dreams, nausea, or sleep changes may be the main thing to watch. Over the next few months, a clinician may review whether symptoms are meaningfully better, unchanged, or worse, and whether another diagnosis or treatment path needs attention.
After longer use, the key question is whether the medication is still helping enough to justify continued use. For autoimmune or inflammatory disease, this review should happen alongside disease-specific monitoring, not instead of it.
When should you get medical help now?
Get prompt care if inflammation-like symptoms come with red flags. LDN should never delay urgent evaluation.
- Fever, stiff neck, confusion, chest pain, or trouble breathing.
- New weakness, numbness, vision loss, severe headache, or trouble speaking.
- Blood in stool, black stools, severe abdominal pain, or repeated vomiting.
- Rapidly spreading rash, facial swelling, or signs of a severe allergic reaction.
- Yellow skin or eyes, dark urine, or severe right-upper-abdominal pain.
- Symptoms of opioid withdrawal after taking naltrexone, such as severe agitation, vomiting, sweating, diarrhea, or muscle pain.
3-min quiz
Start with a clinician-reviewed online visit
If you want to discuss LDN for inflammation-related symptoms, Chia can help you start with an online questionnaire and licensed US provider review. If prescribed, compounded LDN tablets are filled by a state-licensed 503A pharmacy and shipped to your door. A prescription requires medical evaluation and is not guaranteed.
LDN is being studied for anti-inflammatory effects, especially through microglia and nervous-system immune signaling. It is better described as an investigational off-label option for certain inflammation-related symptoms, not a proven general anti-inflammatory.
No. Naltrexone is FDA-approved for substance-use indications, but low-dose naltrexone is not FDA-approved for inflammation, fibromyalgia, autoimmune disease, or chronic pain. Compounded drugs are not FDA-approved.
There is no guaranteed timeline. In clinical practice and studies, response is usually discussed over weeks to months, with attention to pain, function, sleep, and side effects. A clinician should define what counts as a meaningful response.
Naltrexone blocks opioid receptors and can interfere with opioid pain medicines or trigger withdrawal in someone who is opioid-dependent. People using opioids should not start LDN without careful clinician review.
LDN has been discussed or studied in some autoimmune and immune-mediated conditions, but evidence is condition-specific and limited. It should not replace proven disease-specific treatment for autoimmune disease.
LDN should be obtained only with a valid prescription after clinician review. At Chia, the process starts online, but a licensed US provider must decide whether it is clinically appropriate, and a prescription is never guaranteed.
Compounded LDN can be appropriate when prescribed and filled by a properly licensed pharmacy, but compounded medications are not FDA-approved. Safety also depends on your medical history, opioid use, liver risk, pregnancy or breastfeeding status, and other medications.
Ask what diagnosis is being addressed, what benefits are realistic, what side effects to watch for, how opioids or liver history affect safety, and which proven treatments you should continue.
References
- 1.U.S. Food and Drug Administration. Naltrexone hydrochloride tablets prescribing information. FDA drug label, accessed 2026.
- 2.Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory agent in the treatment of chronic pain. Clinical Rheumatology. 2014.
- 3.Vatvani AD, Patel P, Hariyanto TI, Yanto TA. Efficacy and safety of low-dose naltrexone for the management of fibromyalgia: a systematic review and meta-analysis. Korean Journal of Pain. 2024.
- 4.Due Bruun K, Christensen R, Amris K, et al. Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: a randomised, double-blind, placebo-controlled trial. The Lancet Rheumatology. 2024.
- 5.Khan S, Ghafoor R, Kaleem S. Efficacy of Low Dose Naltrexone in Psoriasis. Journal of the College of Physicians and Surgeons--Pakistan. 2020.
- 6.Metyas S, Chen CL, Yeter K, et al. Low Dose Naltrexone in the Treatment of Fibromyalgia. Current Rheumatology Reviews. 2018.
- 7.Radi R, Huang H, Rivera J, et al. Is low-dose naltrexone effective in chronic pain management? The Journal of Family Practice. 2023.
- 8.ClinicalTrials.gov. Low Dose Naltrexone Therapy for Complex Regional Pain Syndrome. NCT06306157. 2024.
- 9.ClinicalTrials.gov. The Preventive Treatment of Migraine With Low-Dose Naltrexone and Acetaminophen Combination. NCT03194555. 2017.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
Find what fits your body and your goals.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
